TNXP

Tonix Pharmaceuticals Holding Corp

Add to Watchlist

Advanced Chart

17.520

+0.120(+0.690%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

17.6075

Open

17.2023

VWAP

17.03

Vol

420.63K

Mkt Cap

130.04M

Low

16.680

Amount

7.16M

EV/EBITDA(TTM)

Total Shares

4.19M

35.99M

EV/OCF(TTM)

P/S(TTM)

1.24

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics and vaccines to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg. Its portfolio consists of central nervous system (CNS), rare disease, immunology, and infectious disease product candidates. The CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Its immunology portfolio includes biologics to address organ transplant rejection, autoimmune diseases and cancer. Its infectious disease portfolio includes a vaccine in development to prevent smallpox and mpox, vaccines to prevent COVID-19, a platform to make fully human monoclonal antibodies (mAbs), to treat COVID-19 and humanized anti-SARS-CoV-2 mAbs. Its product candidates include TNX-102 SL, TNX-4300, TNX-1900, TNX-601 ER and others.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q2

FY2025Q1

2.65M

-6.09%

2.65M

+20.02%

2.55M

+2.74%

Estimates Revision

The market is revising Downward the revenue expectations for Tonix Pharmaceuticals Holding Corp. (TNXP) for FY2025, with the revenue forecasts being adjusted by -16.85% over the past three months. During the same period, the stock price has changed by -53.28%.

Revenue Estimates for FY2025

Revise Downward

-16.85%

In Past 3 Month

Stock Price

Go Down

-53.28%

In Past 3 Month

1 Analyst Rating

299.54% Upside

Wall Street analysts forecast TNXP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TNXP is 70.00 USD with a low forecast of 70.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

299.54% Upside

Current: 17.520

Low

70.00

Averages

70.00

High

70.00

299.54% Upside

Current: 17.520

Low

70.00

Averages

70.00

High

70.00

Noble Capital Markets

Robert LeBoyer

Buy

Reiterates

$70

2025-03-20

Reason

Noble Capital Markets

Robert LeBoyer

Price Target

$70

2025-03-20

Reiterates

Buy

Reason

Alliance Global Partners

James Molloy

Strong Buy

Maintains

$6 → $11

2024-07-22

Reason

Alliance Global Partners

James Molloy

Price Target

$6 → $11

2024-07-22

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Tonix Pharmaceuticals Holding Corp (TNXP.O) is -1.20, compared to its 5-year average forward P/E of -1.31. For a more detailed relative valuation and DCF analysis to assess Tonix Pharmaceuticals Holding Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.31

Current PE

-1.20

Overvalued PE

0.19

Undervalued PE

-2.81

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.98

Current EV/EBITDA

0.98

Overvalued EV/EBITDA

5.74

Undervalued EV/EBITDA

-9.70

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

1.13

Current PS

10.33

Overvalued PS

3.30

Undervalued PS

-1.04

Financials

Annual

Quarterly

FY2024Q4

YoY :

-31.68%

2.58M

Total Revenue

FY2024Q4

YoY :

-17.74%

-22.48M

Operating Profit

FY2024Q4

YoY :

-19.08%

-22.11M

Net Income after Tax

FY2024Q4

YoY :

-99.64%

-9.82

EPS - Diluted

FY2024Q4

YoY :

-35.76%

-14.63M

Free Cash Flow

FY2024Q4

YoY :

+45.02%

54.18

Gross Profit Margin - %

FY2024Q4

YoY :

-57.25%

-604.77

FCF Margin - %

FY2024Q4

YoY :

+18.43%

-856.24

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

591.0K

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

TNXP News & Events

Events Timeline

2025-04-29 (ET)

2025-04-29

09:17:24

Tonix presented preclinical data on gastric cancer models at AACR

2025-04-24 (ET)

2025-04-24

07:58:01

Tonix Pharmaceuticals present data on potential Mpox vaccine TNX-801

2025-04-09 (ET)

2025-04-09

07:04:00

Tonix Pharmaceuticals, Makana to announce collaboration research agreement

News

9.0

04-24Newsfilter

Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025

7.5

04-09Newsfilter

Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix's Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana's Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies

9.0

04-07Newsfilter

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting